175P - Expression and clinical significance of androgen receptor in triple-negative breast cancer

Date 28 September 2014
Event ESMO 2014
Session Poster Display session
Topics Breast Cancer
Pathology/Molecular Biology
Translational Research
Basic Scientific Principles
Basic Principles in the Management and Treatment (of cancer)
Presenter Yuka Asano
Citation Annals of Oncology (2014) 25 (suppl_4): iv58-iv84. 10.1093/annonc/mdu326
Authors Y. Asano1, S. Kashiwagi1, K. Kurata2, T. Morisaki1, S. Noda1, H. Kawajiri1, T. Takashima3, N. Onoda1, K. Maeda1, K. Hirakawa1
  • 1Surgical Oncology, Osaka City University Graduate School of Medicine, 545-8585 - Osaka/JP
  • 2Surgical Oncology, Osaka City University Medical School, 545-8585 - Osaka/JP
  • 3Dept. Surgical Oncology, Osaka City University Graduate School of Medicine, 545-8585 - Osaka/JP



Breast cancer is also a heterogeneous tumor including a variety of subtypes with different biological behaviors, clinicopathologic features and molecular characteristics. The responses to treatment and the prognosis of different subtypes of breast cancer are also markedly different. Triple-negative breast cancer (TNBC), a subtype of breast tumor with ER negative, PR negative, and HER2 negative, shows a poor prognosis because of a frequent recurrence. Androgen receptor (AR) is involved in the pathogenesis of breast cancer, but its role is not clearly defined. This study was to explore the expression of AR and its relationship with clinicopathologic parameters in TNBC.


This study investigated a consecutive series of 1036 cases of sporadic invasive breast carcinoma. Immunohistological assays were performed to determine the expression of AR in 190 of TNBC. The relationships between AR expression and clinicopathologic data and prognosis were analyzed. ER, PR, Ki67 and AR status were assessed by immunohistochemistry. HER2 status was assessed by either immunohistochemistry or fluorescent in situ hybridization. The immunostaining results for ER, PR, and AR were assessed semiquantitatively and reported as positive if more than 1% of cells immunostained in a tumor.


Of informative 1036 breast cancer cases, triple-negative phenotype was 190 (18.3%). TNBC patients experienced a poorer prognosis in comparison to non-TNBC patients (p < 0.001, log-rank). The cases with AR expression were found in 56 patients (29.5%) in TNBC. In 190 TNBC cases, the prognosis of AR-negative patients was significantly poor (p = 0.019, log-rank), and it was an independent indicator of a poor prognosis by multivariate analyses (p = 0.039).


AR might be a prognostic marker and possible endocrine target for therapy in patients with TNBC.


All authors have declared no conflicts of interest.